HIV-1 drug resistance and genetic diversity in people with HIV-1 in Cape Verde
- 12 February 2024
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 38 (8) , 1101-1110
Abstract
Objectives: To characterize the genetic diversity and drug resistance profiles of people with HIV-1 failing ART in Cape Verde (CV). Design: Cross-sectional study conducted between January 2019 and December 2021 in 24 health centres on the islands of Santiago and São Vicente. Methods: The HIV-1 pol gene was sequenced in individuals with a detectable viral load. HIV-1 genetic diversity was determined by phylogenetic analysis. Drug resistance mutation patterns and resistance phenotypes were estimated using the Stanford algorithm. Results: Viral load was detected in 73 of 252 (29%) enrolled participants and sequencing data were produced for 58 (79%) participants. CRF02 AG strains predominated (46.5%), followed by subtype G (22.4%). Most patients (80%) had mutations conferring resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) (67%), nucleoside reverse transcriptase inhibitors (55%), integrase inhibitors (10%) and/or protease inhibitors (7%) used in Cape Verde, a significant increase compared with a study conducted in 2010–2011. The most common mutations were M184V/I (43%), K103N/S (36%) and G190A/S (19%). NNRTI resistance was associated with younger age and exposure to two or more drug regimens. Conclusion: The HIV-1 epidemic in Cape Verde is mainly driven by CRF02_AG and subtype G. Resistance to NNRTIs and/or NRTIs is highly prevalent and resistance to LPV/r and DTG is emerging. Our results support the use of DTG-based first-line ART and protease inhibitor-based regimens for patients with virological failure, but emerging resistance to LPV/r and DTG is a concern. Continued monitoring of drug resistance is essential to ensure adequate healthcare for PWH in Cape Verde.Keywords
All Related Versions
This publication has 45 references indexed in Scilit:
- Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIVNew England Journal of Medicine, 2021
- HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistanceInternational Journal of Antimicrobial Agents, 2021
- HIV Drug Resistance in Children and Adolescents: Always a Challenge?Current Epidemiology Reports, 2021
- Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second‐line ARTJournal of the International AIDS Society, 2020
- Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in MaliArchives de Pédiatrie, 2019
- Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysisThe Lancet Infectious Diseases, 2019
- HIV Drug Resistance — An Emerging Threat to Epidemic ControlNew England Journal of Medicine, 2017
- Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in MauritaniaJournal of Medical Virology, 2013
- Phylodynamics of HIV-1 subtype F1 in Angola, Brazil and RomaniaInfection, Genetics and Evolution, 2012
- Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients☆Infection, Genetics and Evolution, 2009